Kelly Shi
Stock Analyst at Jefferies
(1.70)
# 3,109
Out of 4,734 analysts
26
Total ratings
32%
Success rate
-8.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelly Shi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TIL Instil Bio | Upgrades: Buy | $11 → $52 | $19.61 | +165.17% | 2 | Jan 7, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Buy | $18 → $14 | $4.41 | +217.46% | 2 | Dec 16, 2024 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $13 → $19 | $16.46 | +15.43% | 2 | Sep 11, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $174 → $196 | $131.06 | +49.55% | 2 | Aug 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | $21 | $7.07 | +197.03% | 1 | Aug 13, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $37 | $13.67 | +170.67% | 1 | Jun 28, 2024 | |
| PROK ProKidney | Maintains: Buy | $15 → $6 | $1.79 | +235.20% | 2 | Jun 10, 2024 | |
| PTCT PTC Therapeutics | Maintains: Buy | $35 → $46 | $45.25 | +1.66% | 3 | May 20, 2024 | |
| INCY Incyte | Initiates: Buy | $81 | $73.47 | +10.25% | 1 | Feb 23, 2024 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $35 | $25.31 | +38.29% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $2.60 | +1,284.62% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $45.82 | -65.08% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $43.70 | -8.47% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $5.69 | +251.49% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $3.22 | +148.45% | 1 | Aug 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $0.94 | +2,775.71% | 1 | Mar 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $52 | $14.21 | +265.94% | 1 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.05 | +2,471.43% | 1 | Apr 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.77 | +1,762.30% | 1 | Mar 8, 2021 |
Instil Bio
Jan 7, 2025
Upgrades: Buy
Price Target: $11 → $52
Current: $19.61
Upside: +165.17%
Foghorn Therapeutics
Dec 16, 2024
Maintains: Buy
Price Target: $18 → $14
Current: $4.41
Upside: +217.46%
Centessa Pharmaceuticals
Sep 11, 2024
Maintains: Buy
Price Target: $13 → $19
Current: $16.46
Upside: +15.43%
Ascendis Pharma
Aug 13, 2024
Maintains: Buy
Price Target: $174 → $196
Current: $131.06
Upside: +49.55%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: $21
Current: $7.07
Upside: +197.03%
Syndax Pharmaceuticals
Jun 28, 2024
Initiates: Buy
Price Target: $37
Current: $13.67
Upside: +170.67%
ProKidney
Jun 10, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.79
Upside: +235.20%
PTC Therapeutics
May 20, 2024
Maintains: Buy
Price Target: $35 → $46
Current: $45.25
Upside: +1.66%
Incyte
Feb 23, 2024
Initiates: Buy
Price Target: $81
Current: $73.47
Upside: +10.25%
ArriVent BioPharma
Feb 20, 2024
Initiates: Buy
Price Target: $35
Current: $25.31
Upside: +38.29%
Feb 5, 2024
Initiates: Buy
Price Target: $36
Current: $2.60
Upside: +1,284.62%
Nov 11, 2022
Initiates: Buy
Price Target: $16
Current: $45.82
Upside: -65.08%
Aug 15, 2022
Initiates: Buy
Price Target: $40
Current: $43.70
Upside: -8.47%
Aug 15, 2022
Initiates: Buy
Price Target: $20
Current: $5.69
Upside: +251.49%
Aug 3, 2022
Initiates: Buy
Price Target: $8
Current: $3.22
Upside: +148.45%
Mar 4, 2022
Initiates: Buy
Price Target: $27
Current: $0.94
Upside: +2,775.71%
Aug 3, 2021
Initiates: Buy
Price Target: $52
Current: $14.21
Upside: +265.94%
Apr 13, 2021
Initiates: Buy
Price Target: $27
Current: $1.05
Upside: +2,471.43%
Mar 8, 2021
Initiates: Buy
Price Target: $33
Current: $1.77
Upside: +1,762.30%